Andrew Doig, MS – Preclinical Development
Andrew obtained a BS degree in Biological Sciences from the University of Natal, South Africa. After working for several years for a biotech company and at Baylor College of Medicine, he obtained his MS in Toxicology from the University of Texas Graduate School of Biomedical Sciences in Houston, Texas. He returned to Baylor College of Medicine to work in the Molecular and Human Genetics Department. Andrew worked for three major biotech companies before joining STILLMEADOW, Inc. in July 2006. He works as a toxicology study director and is involved in establishing a preclinical development department at Stillmeadow.